Please join Dr. John Carpenter from the University of Colorado and Dr. Mustafa Kansiz from PSC, in this comprehensive webinar to learn how submicron infrared Raman analysis (O-PTIR) is revolutionizing biopharmaceutical particle characterization and immunogenicity risk assessment.
Detecting and characterizing subvisible particles below 10 microns—especially protein aggregates and foreign contaminants in biologic therapies—has long been a critical analytical challenge. Traditional direct infrared techniques like FTIR are effectively limited to particles above 10–20 microns, leaving the most immunologically relevant particle fraction undetectable and potentially dangerous to patients.
Optical Photothermal Infrared Spectroscopy (O-PTIR) is changing that.
This breakthrough technique enables label-free, high-resolution detection and chemical identification of particles down to 200 nm, overcoming the spectral size/shape artifacts and spatial resolution limits of direct IR techniques and the fluorescence interference of traditional Raman spectroscopy. O-PTIR delivers rapid, non-destructive, and automated particle analysis in even the most complex biopharmaceutical formulations.
Join us to discover how O-PTIR is transforming biopharmaceutical quality control—finally making it possible to detect and characterize the particle size fractions that matter most for drug safety and patient health.
Webinar Highlights:
✅ Breaking the 10-micron barrier – Detecting and characterizing protein aggregates, foreign particles, and contaminants down to 200 nm in biologic formulations
✅ O-PTIR vs. Traditional Techniques – 30x improvement in spatial resolution over FTIR with artifact-free imaging and spectroscopy, plus fluorescence-free IR analysis
✅ Automated Reliable Analysis – Trimodal approach combining IR, Raman, and fluorescence microscopy on a single platform
✅ Real-World Applications – Case studies including nasal spray analysis, inhaler formulations, IV system contamination, monoclonal antibody characterization, and protein-silicon oil interactions
✅ Immunogenicity Risk Assessment – Understanding how particle size, composition, and protein-foreign material combinations impact patient safety and treatment efficacy
Who Should Attend?
🔬 Biopharmaceutical Researchers – Scientists studying protein aggregation, formulation development, and drug immunogenicity
🏥 Analytical Labs & QC Teams – Labs specializing in biopharmaceutical testing, particle characterization, and regulatory compliance
🌍 Regulatory & Quality Experts – Professionals focused on drug safety, particle control, and immunogenicity risk management
🧪 Industry Scientists – Experts in pharmaceutical manufacturing, formulation science, and bioprocess development interested in advanced particle analysis